Funding for this research was provided by:
Text and Data Mining valid from 2018-05-09
Received: 15 November 2017
Accepted: 3 April 2018
First Online: 9 May 2018
: This study was a secondary analysis of clinical trial data. Written informed consent was obtained from all study subjects who participated in the clinical trial, and the study protocol was approved by the Institutional Review Board at each study site.
: Corresponding author Peter D.R. Higgins is the Director of the IBD Program at the University of Michigan in Ann Arbor, MI. Authors Marcoli Cyrille, Brian G. Ortmeier, and Gary Globe are salaried employees and shareholders of Amgen Inc. (Thousand Oaks, CA). Author Hema N. Viswanathan was a salaried employee and shareholder of Amgen Inc. of Thousand Oaks, CA at the time this work was completed, and is currently with Allergan Inc. of Irvine, CA. Author Donald L. Patrick is employed by the University of Washington (Seattle, WA). Authors Kendra DeBusk, Kristina Fitzgerald, and Sarah M. Donelson are salaried employees and shareholders of Genentech Inc. (South San Francisco, CA). Authors Gale Harding, Nancy Leidy, Hilary Wilson, and Dennis Revicki are salaried employees of Evidera in Bethesda, MD, and are not allowed to accept remuneration from any clients for their services. Evidera received funding from Amgen Inc. (Thousand Oaks, CA) to participate in the study and the development of this manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.